A phase 3 trial of azacitidine versus a semi-intensive fludarabine and cytarabine schedule in older patients with untreated acute myeloid leukemia.
Susana VivesDavid Martínez-CuadrónJuan Bergua BurguesLorenzo AlgarraMar TormoMaría Pilar Martínez-SánchezJosefina SerranoPilar HerreraFernando RamosOlga SalameroEsperanza LavillaJosé L López-LorenzoCristina GilBelén VidrialesJose F FalantesAlfons SerranoJorge LabradorMaría J SayasMaría Á FoncillasMaría L Amador BarcielaMaría Teresa OlaveMercedes ColoradoAdriana GascónMaría Á FernándezAdriana SimieleManuel M Pérez-EncinasRebeca Rodríguez-VeigaOlga GarcíaJoaquín Martínez-LópezEva BarragánBruno PaivaMiguel Á SanzPau Montesinosnull nullPublished in: Cancer (2021)
FLUGA achieved more remissions after 3 cycles, but the 1-year OS rate was superior with AZA. However, long-term outcomes were disappointing in both arms (3-year OS rate, 10% vs 5%). This study supports the use of an AZA backbone for future combinations in elderly patients with AML.